Search

Learn about some of the latest treatments for thyroid cancer and clinical trials that have been led by researchers from MSK.

… Thursday, July 31, 2025 Thyroid cancer is the most common form of cancer found in the  head and neck area and is diagnosed in more than 44,000 people in the United States every year.  There are many  different types of thyroid cancer. Some, such as early-stage papillary cancers, grow slowly and are easy

In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.

… Monday, June 3, 2024 In a proof-of-concept study, researchers at Memorial Sloan Kettering Cancer Center (MSK) and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone

The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.

… Monday, December 28, 2020 Summary Researchers at Memorial Sloan Kettering have learned how chromosomal instability allows cancer cells to avoid immune defenses and metastasize (spread). The discovery opens up potential new avenues for treatment. Cancer cells are known for spreading genetic chaos. As

On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.

… Friday, August 5, 2022 On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low  breast cancer  that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial

With notable cases of pancreatic cancer in the news this year, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the disease and sharing some of the encouraging breakthroughs in research and treatment.

… Monday, November 23, 2020 With notable cases of pancreatic cancer in the news this year, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the disease and sharing some of the encouraging breakthroughs in research and treatment. The session was moderated

Memorial Sloan Kettering Cancer Center (MSK) has welcomed Whitney Snider, MD, MBA, as the inaugural Managing Partner of MSK Ventures – a dedicated investment pool that will raise and direct funds to high-growth, early-stage startups created and/or nurtured by MSK faculty and staff.

… Tuesday, January 20, 2026 Memorial Sloan Kettering Cancer Center (MSK) has welcomed Whitney Snider, MD, MBA, as the inaugural Managing Partner of MSK Ventures – a dedicated investment pool that will raise and direct funds to high-growth, early-stage startups created and/or nurtured by MSK faculty and

A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan Kettering's new Brain Tumor Center (BTC).

… Thursday, January 31, 2008 A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan Kettering’s new Brain Tumor Center (BTC). Established in 2007, the BTC is designed to achieve fundamental new

After two studies examined the safety of eliminating axillary lymph node dissection (ALND) for some breast cancer patients, Memorial Sloan Kettering Cancer Center further tested their conclusions, confirmed the approach’s applicability and changed clinical practice.

… Thursday, June 23, 2016 Axillary lymph node dissection (ALND) is no longer the standard approach to the management of all breast cancer patients with metastases to the sentinel lymph nodes. Advances in mammography screening have resulted in lower nodal disease burden in women with axillary metastases

Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.

… Tuesday, October 16, 2018 Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize . Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells. Dr.

The Ralph Lauren Corporate Foundation announced today that it's providing $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities. The funding will benefit institutions including the Memorial Sloan Kettering (MSK) Ralph Lauren Center in Harlem.

… Wednesday, May 11, 2022 The Ralph Lauren Corporate Foundation announced today that it will provide $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities in the United States. The